Myst Therapeutics Appoints George Smith as Vice President of Business Operations
LOS ANGELES--(BUSINESS WIRE)--Myst Therapeutics (Myst), a preclinical stage biotechnology company focused on developing selected TIL-based autologous T cell (PuriT?) therapy products for cancer, announced the appointment of George Smith, PhD, MBA as Vice President of Business Operations. Dr. Smith, who brings to Myst over 20 years of successful drug development experience at both biotechnology and global pharmaceutical companies, was previously the founder and lead for the Cell and Gene Therapy
